Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews published research on ergothioneine and mushroom-derived supplements. It is informational only and is not medical advice. Not medical advice. Consult a qualified healthcare professional before adding any supplement to your routine, particularly if you have a chronic health condition or take prescription medications.

The question this compound raises

If you have spent time researching longevity supplements in the past two years, you may have encountered “ergothioneine” grouped alongside NMN and resveratrol. The positioning varies: some supplement brands describe it as an exceptionally potent cellular antioxidant; others lead with a neuroprotection angle; a few point to the fact that humans have a dedicated transporter protein for it, which they take as evidence of evolutionary necessity.

Most of those framings move faster than the available human evidence warrants. But the underlying biology is genuinely distinctive, the emerging cohort data from Asia is worth reading carefully, and the Japanese dietary angle here is concrete rather than speculative.

What ergothioneine is — and why the transporter is notable

L-ergothioneine (EGT) is a sulfur-containing amino acid derivative — specifically a betaine of 2-thiolhistidine — synthesized by fungi and certain bacteria but not by humans or other animals. Humans acquire it entirely through diet, primarily through foods that contain or are grown with fungi.

What distinguishes EGT from most dietary antioxidants is the dedicated transport protein: OCTN1 (encoded by the SLC22A4 gene). This transporter was characterized in a 2005 paper in PNAS by Gründemann and colleagues, who identified it as the specific ergothioneine transporter after it had been provisionally classified as a general organic cation transporter. OCTN1 is expressed at high density in cells with elevated oxidative stress exposure — red blood cells, neutrophils, liver, kidney, bone marrow, lens of the eye, and neurons.

The existence of a dedicated, evolutionarily conserved transporter for a dietary compound is unusual. Most dietary antioxidants enter cells via nonspecific diffusion or general organic transporter pathways. The specificity of OCTN1 for EGT led Bruce Ames and colleagues, in a 2018 PNAS analysis of “longevity vitamins,” to include ergothioneine among compounds that may be conditionally essential micronutrients rather than simply supplementary antioxidants.

That hypothesis remains unconfirmed by controlled human trials. What the transporter does provide is a mechanism for understanding why dietary intake — and variation in dietary intake across populations — might produce measurable physiological differences.

Japanese mushrooms as dietary sources

Ergothioneine is synthesized by fungi and is not produced de novo by plants or animals. Among edible foods, mushrooms are by far the most concentrated source.

Food chemistry research — including studies from the Beelman laboratory at Penn State and Japanese food science groups — has characterized EGT content across common species:

Mushroom	Japanese name	Approximate EGT (dry weight)
Porcini (Boletus edulis)	ヤマドリタケ	~3–5 mg/g (highest common species)
Shiitake (Lentinus edodes)	しいたけ	~1.5–2.5 mg/g
Maitake (Grifola frondosa)	まいたけ	~0.5–1.5 mg/g
King oyster / eringi (Pleurotus eryngii)	えりんぎ	~0.3–1.0 mg/g
Button / portobello (Agaricus bisporus)	マッシュルーム	~0.2–0.5 mg/g

These are laboratory measurements and vary by growing conditions, substrate, and maturity; they are useful for relative comparisons, not as precise dosage guides. The directional finding is consistent across studies: shiitake and maitake are meaningfully richer EGT sources than the button mushrooms that dominate Western grocery shelves.

Japan’s per-capita mushroom consumption is among the highest globally. Maitake appears regularly in tempura and hotpot; shiitake goes into stock, sauté, and simmered dishes; eringi is a common stir-fry ingredient. This habitual exposure translates to substantially higher estimated dietary EGT intake than in populations with low mushroom consumption. Whether that dietary difference produces measurable biological differences is what the cohort research attempts to address.

What cohort data shows on cognitive outcomes

The most-cited human evidence involves longitudinal research from Singapore, where the National University of Singapore has conducted aging studies in Chinese elderly populations with detailed dietary records.

Feng Lei and colleagues (2019, Journal of Alzheimer’s Disease) analyzed data from 663 community-dwelling adults aged 60 and older in Singapore followed over approximately six years. Participants who consumed mushrooms at a frequency of two or more servings per week showed odds of mild cognitive impairment roughly 50% lower than participants who consumed less than one serving per week (OR ≈ 0.43, 95% CI 0.23–0.78), after adjusting for age, sex, education, physical activity, smoking, alcohol use, cardiovascular conditions, and overall dietary pattern.

This is an observational association, not a controlled experiment. Mushroom consumption could function as a proxy for a broader dietary quality pattern; it was not possible in this design to isolate which constituent of mushrooms was responsible. The authors identified ergothioneine as a leading candidate based on mushrooms’ unique EGT content and the compound’s known penetration into neural tissue, but that attribution is hypothesis-generating, not established.

Separate research from Cheah and colleagues, published in Biochemical and Biophysical Research Communications across multiple years, measured plasma ergothioneine concentrations in elderly Singaporean cohort participants and found that lower plasma EGT was associated with greater cognitive decline over follow-up. Koh et al. (2019, Journal of Alzheimer’s Disease) reported that plasma EGT levels in older adults with mild cognitive impairment were significantly lower than in age-matched healthy controls.

Taken together, these cohort findings are consistent: populations with higher mushroom intake and higher plasma EGT levels appear to have lower rates of cognitive decline. The association is present across multiple designs and independent research groups. What it cannot tell you is whether ergothioneine is the active variable, and whether raising intake changes outcomes — questions only a well-designed RCT can answer.

Early trial data and cellular mechanisms

At the cellular level, EGT accumulates in mitochondria and appears to protect against oxidative damage to mitochondrial membrane lipids and DNA in cell culture and animal models. Neutrophils concentrate EGT as a reservoir antioxidant, releasing it under oxidative stress. Liver and kidney cells maintain intracellular EGT concentrations substantially above plasma levels through active OCTN1-mediated uptake, suggesting the body prioritizes accumulating this compound in high-demand tissues.

Human trial data at supplement doses is early but not absent. Several small RCTs in older Japanese and Singaporean adults, using ergothioneine at doses of 5–30 mg/day over 8–12 weeks, have reported improvements in oxidative stress biomarkers and some cognitive function measures compared to placebo. The trials are small (n typically under 50), of short duration, and have not been independently replicated at scale. The direction of effect is consistent with the cohort associations; the evidence remains preliminary in humans.

One comparison that clarifies the EGT situation: vitamin E, resveratrol, and other antioxidant compounds with compelling preclinical profiles have repeatedly failed to produce the same effects in adequately powered human trials. EGT has a more specific cellular uptake profile than these compounds, and the cohort human data is a meaningful additional data layer, but the gap between preclinical mechanism and confirmed human outcome is the central unknown.

Side effects and interactions

At dietary intake levels — estimated at 1–10 mg/day in high-mushroom-consuming populations — ergothioneine has no documented adverse effects in the published literature. In the limited supplement trial data available, doses of 5–30 mg/day over 8–12 weeks produced no serious adverse events.

One pharmacological note: EGT shares the OCTN1 transporter with L-carnitine. At pharmacological doses well above current supplement ranges, competition for transporter occupancy is theoretically possible, with implications for carnitine uptake in muscle. At dietary and current supplement dose ranges (5–25 mg/day), this is not an established clinical concern, but it is worth disclosing to a clinician if you take carnitine therapeutically.

No documented interactions with anticoagulants, cardiovascular medications, or common longevity supplements at current dose ranges have been reported. Given the limited depth of the human trial literature, the absence of documented interactions partly reflects limited study rather than comprehensive clearance.

Sourcing: food, mushroom extract, and ergothioneine supplements

Food-first remains the most grounded approach. Adding two to three servings of shiitake or maitake per week — the threshold in the Singapore cohort analysis — is achievable, inexpensive, and comes with beta-glucan polysaccharides, dietary fiber, and culinary depth that no capsule replicates. Dried shiitake available internationally from Japanese grocers retains ergothioneine; cooking does not substantially degrade it.

Dried shiitake and maitake mushroom products on Amazon US include Japanese-origin dried options suitable for both culinary use and as consistent EGT sources.

For standalone ergothioneine supplements: pure L-ergothioneine capsules have entered the market recently, made feasible by fermentation-based production methods that allow scalable synthesis. DoNotAge and a small number of specialist longevity supplement brands now offer EGT at doses of 5–25 mg/day.

Ergothioneine supplement search on Amazon US currently returns a limited but growing selection. Practical buying filters: confirmed L-ergothioneine content stated by weight per capsule, fermentation-derived source declared, third-party certificate of analysis available from the seller. Ergothioneine production costs more than most commodity supplements; products priced very low per milligram are worth scrutinizing for source documentation.

Mushroom complex supplements (commonly combining lion’s mane, maitake, and reishi for beta-glucan content) are widely available and may contribute some EGT alongside their better-characterized immunomodulatory compounds. EGT content is typically not measured or guaranteed in these formulations; they are not a reliable way to target ergothioneine intake specifically.

Who should hold off

• Pregnant or nursing women (no safety data at supplemental doses for this population)
• Anyone taking L-carnitine therapeutically — the theoretical OCTN1 transporter competition is not an established clinical concern at current doses, but disclosure to a clinician is appropriate
• Individuals with conditions affecting the OCTN1 transporter — certain variants in the SLC22A4 gene have been associated with Crohn’s disease susceptibility in genetic studies; the implications for EGT supplementation in these individuals are not characterized in the literature

For most adults, the risk profile at food intake levels and at current low-dose supplement ranges appears clean in the available data. The calibrated framing: ergothioneine has more specific cellular biology and more intriguing preliminary human cohort data than most newer entries in the longevity supplement category — but the controlled human outcome trials that would justify confident recommendations have not yet been completed. The dietary approach — eating more shiitake and maitake regularly — carries no meaningful downside, aligns with the cohort data that exists, and is the most reasonable starting point while the trial literature matures.

---

See also: Japanese medicinal mushroom complex buyer’s guide, CoQ10 vs ubiquinol — what cardiac RCTs show, Japanese longevity diet beginner’s guide.